These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 16455452)
21. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924 [TBL] [Abstract][Full Text] [Related]
22. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Xu ZW; Friess H; Büchler MW; Solioz M Cancer Chemother Pharmacol; 2002 Jun; 49(6):504-10. PubMed ID: 12107556 [TBL] [Abstract][Full Text] [Related]
23. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Bernhaus A; Ozsvar-Kozma M; Saiko P; Jaschke M; Lackner A; Grusch M; Horvath Z; Madlener S; Krupitza G; Handler N; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T Invest New Drugs; 2009 Oct; 27(5):393-401. PubMed ID: 18841326 [TBL] [Abstract][Full Text] [Related]
24. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494 [TBL] [Abstract][Full Text] [Related]
25. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. Singla S; Pippin JA; Drebin JA Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710 [TBL] [Abstract][Full Text] [Related]
26. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. Halloran CM; Ghaneh P; Shore S; Greenhalf W; Zumstein L; Wilson D; Neoptolemos JP; Costello E J Gene Med; 2004 May; 6(5):514-25. PubMed ID: 15133762 [TBL] [Abstract][Full Text] [Related]
27. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796 [TBL] [Abstract][Full Text] [Related]
28. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918 [TBL] [Abstract][Full Text] [Related]
29. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway. Liu J; Huang Y; Liu Y; Chen Y Med Sci Monit; 2019 Aug; 25():6085-6096. PubMed ID: 31412018 [TBL] [Abstract][Full Text] [Related]
30. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Simon PO; McDunn JE; Kashiwagi H; Chang K; Goedegebuure PS; Hotchkiss RS; Hawkins WG Int J Cancer; 2009 Aug; 125(4):942-51. PubMed ID: 19405118 [TBL] [Abstract][Full Text] [Related]
31. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Kulp SK; Yang YT; Hung CC; Chen KF; Lai JP; Tseng PH; Fowble JW; Ward PJ; Chen CS Cancer Res; 2004 Feb; 64(4):1444-51. PubMed ID: 14973075 [TBL] [Abstract][Full Text] [Related]
32. OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo. Ding L; Ren C; Yang L; Wu Z; Li F; Jiang D; Zhu Y; Lu J Drug Des Devel Ther; 2021; 15():1797-1810. PubMed ID: 33958857 [TBL] [Abstract][Full Text] [Related]
33. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491 [TBL] [Abstract][Full Text] [Related]
35. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Strouch MJ; Milam BM; Melstrom LG; McGill JJ; Salabat MR; Ujiki MB; Ding XZ; Bentrem DJ Pancreas; 2009 May; 38(4):409-15. PubMed ID: 19142175 [TBL] [Abstract][Full Text] [Related]
36. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Nakashima M; Adachi S; Yasuda I; Yamauchi T; Kawaguchi J; Itani M; Yoshioka T; Matsushima-Nishiwaki R; Hirose Y; Kozawa O; Moriwaki H Cancer Lett; 2011 Dec; 313(2):218-25. PubMed ID: 21999932 [TBL] [Abstract][Full Text] [Related]
37. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Carón RW; Yacoub A; Li M; Zhu X; Mitchell C; Hong Y; Hawkins W; Sasazuki T; Shirasawa S; Kozikowski AP; Dennis PA; Hagan MP; Grant S; Dent P Mol Cancer Ther; 2005 Feb; 4(2):257-70. PubMed ID: 15713897 [TBL] [Abstract][Full Text] [Related]
38. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE Clin Cancer Res; 2005 May; 11(9):3433-8. PubMed ID: 15867245 [TBL] [Abstract][Full Text] [Related]
39. Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Mistafa O; Stenius U Biochem Pharmacol; 2009 Nov; 78(9):1115-26. PubMed ID: 19540829 [TBL] [Abstract][Full Text] [Related]
40. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]